Skip to content
    Reviews

    Structured exercise and cardiac outcomes during anthracycline or anti-HER2 therapy in breast cancer: systematic review and meta-analysis of randomized trials

    Cobreros-Mielgo et alSupportive Care in Cancer

    Cardiotoxicity remains a significant clinical concern during anthracycline- and anti-HER2-based chemotherapy regimens for breast cancer. A systematic review and meta-analysis of randomized controlled trials evaluated whether structured exercise interventions, compared to usual care, preserve cardiac function—specifically left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and cardiac biomarkers—in women undergoing these cardiotoxic regimens.
    Across seven identified trials (comprising nine reports and 513 participants), quantitative synthesis for the primary window (baseline to end of anthracycline therapy, approximately 4 months) was feasible in only two trials. The pooled random-effects analysis demonstrated no significant between-group differences in LVEF changes (mean difference [MD] 0.07, 95% CI −1.38 to 1.52; I² = 28.2%) or GLS changes (MD −0.10, 95% CI −0.79 to 0.58; I² = 0%). The wide confidence intervals encompass potential benefit, no effect, or harm.
    Assessment via the Cochrane RoB 2 tool identified some concerns or a high risk of bias across most trials, and GRADE assessment indicated low certainty of evidence. Additionally, biomarker data were too heterogeneous for quantitative pooling, and trials did not report comparative clinical cardiovascular events, overall survival, or formal evaluations of heart failure with preserved ejection fraction (HFpEF). Consequently, existing randomized data do not confirm a consistent cardioprotective benefit of structured exercise on subclinical or clinical cardiotoxicity parameters during treatment.

    Key Takeaways

    • In a meta-analysis of randomized trials, structured exercise showed no statistically significant difference compared with usual care in preserving left ventricular ejection fraction (MD 0.07, 95% CI −1.38 to 1.52; I² = 28.2%) or global longitudinal strain (MD −0.10, 95% CI −0.79 to 0.58; I² = 0%) at the end of anthracycline treatment.
    • Current randomized trial evidence provides low certainty due to wide confidence intervals compatible with benefit, no effect, or harm, alongside high risk of bias or some methodological concerns across most included studies.
    Read the original sourceSupportive Care in Cancer